Hodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature

References

• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa1609324
   PubMed Web of Science ®Google Scholar
• Miranda MB, Lauseker M, Kraus MP, et al. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV. Leukemia. 2016;30(6):1255–1262. doi:10.1038/leu.2016.20
   PubMed Web of Science ®Google Scholar
• Millett R, Aggarwal A, Tabbara I, Nassereddine S. Chronic myeloid leukemia as secondary malignancy following the treatment of Hodgkin lymphoma: a case series. Anticancer Res. 2019;39(8):4333–4335. doi:10.21873/anticanres.13600. PMID: 31366526.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–1671. doi:10.1038/leu.2016.104
   PubMed Web of Science ®Google Scholar
• Gunther JR, Pinnix CC, Glober GR, et al. Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: does incomplete ABVD lead to inferior outcomes? EJHaem. 2020;1(1):272–276. doi:10.1002/jha2.1
   PubMedGoogle Scholar
• Ozawa MG, Ewalt MD, Gratzinger D. Dasatinib-related follicular hyperplasia: an underrecognized entity with characteristic morphology. Am J Surg Pathol. 2015;39(10):1363–1369. doi:10.1097/PAS.0000000000000488
   PubMed Web of Science ®Google Scholar
• Paydas S. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect? Crit Rev Oncol Hematol. 2014;89(2):242–247. doi:10.1016/j.critrevonc.2013.10.005
   PubMed Web of Science ®Google Scholar
• Fox LC, Cummins KD, Costello B, et al. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv. 2017;1(13):802–811. doi:10.1182/bloodadvances.2016003889
   PubMed Web of Science ®Google Scholar
• Climent N, Plana M. Immunomodulatory activity of tyrosine kinase inhibitors to elicit cytotoxicity against cancer and viral infection. Front Pharmacol. 2019;10:1232. doi:10.3389/fphar.2019.01232
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Farkas DK, Christiansen CF, Hasselbalch HC, Sørensen HT. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish Population-Based Cohort Study. Blood. 2011;118(25):6515–6520. doi:10.1182/blood-2011-04-348755
   PubMed Web of Science ®Google Scholar
• Rebora P, Czene K, Antolini L, et al. Are chronic myeloid leukemia patients more at risk for second malignancies? A Population-Based Study. Am J Epidemiol. 2010;172(9):1028–1033. doi:10.1093/aje/kwq262
   PubMed Web of Science ®Google Scholar
• Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118(16):4353–4358. doi:10.1182/blood-2011-06-362889
   PubMed Web of Science ®Google Scholar
• Helbig G, Bober G, Seweryn M, et al. Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience. Mediterr J Hematol Infect Dis. 2015;7(1):e2015003. doi:10.4084/mjhid.2015.003
   PubMedGoogle Scholar
• Kumar V, Garg M, Chaudhary N, Chandra AB. An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. PeerJ. 2018;6:e4342. doi:10.7717/peerj.4342
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, O’Brien S, et al. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019;109(5):545–552. doi:10.1007/s12185-019-02620-2
   PubMed Web of Science ®Google Scholar
• Nakazato T, Iriyama N, Tokuhira M, et al. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors. Med Oncol. 2018;35(7):99. doi:10.1007/s12032-018-1159-7
   PubMed Web of Science ®Google Scholar
• Cai Z, Liu S, Zi J, Ma J, Ge Z. A case of primary gastric diffuse large B-cell lymphoma occurring in chronic myeloid leukemia. Onco Targets Ther. 2019;12:5917–5923. doi:10.2147/OTT.S212838
   PubMed Web of Science ®Google Scholar
• Fujiwara SI, Shirato Y, Ikeda T, et al. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia. Int J Hematol. 2018;107(6):712–715. doi:10.1007/s12185-017-2378
   PubMed Web of Science ®Google Scholar
• Moridaira K, Tamura J, Saitoh T, et al. Non-Hodgkin’s lymphoma following acute myeloid leukemia in complete remission. Acta Haematol. 1998;100(2):97–98. doi:10.1159/000040875
   PubMed Web of Science ®Google Scholar
• Gajendra S, Sharma A, Sharma R, et al. Hodgkin lymphoma in a case of chronic myeloid leukemia treated with tyrosine kinase inhibitors. Turk Patoloji Derg. 2019;35(1):74–78. doi:10.5146/tjpath.2016.01368
   PubMedGoogle Scholar
• Ferrario A, Radaelli F, Goldaniga M, et al. ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma. Leuk Res. 2010;34(10):e280–e281. doi:10.1016/j.leukres.2010.05.004
   PubMed Web of Science ®Google Scholar
• Umakanthan JM, Iqbal J, Batlevi CL, et al. Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. Br J Haematol. 2019;184(5):744–752. doi:10.1111/bjh.15702
   PubMed Web of Science ®Google Scholar